AbbVie : ABBV

All AbbVie Articles

587 Articles

Joel South | May 22, 2026 at 7:36 AM EDT

The Dividend Stocks That Can Replace a $65,000 Income and What They’ll Cost You

Replacing a real paycheck with dividends is the cleanest version of financial independence. The income target here is $65,000 per…

Michael Williams | May 21, 2026 at 7:30 AM EDT

Why retirees are banking on SCHD’s 15-year unbroken dividend streak

The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) has built its reputation on paying reliable, growing quarterly distributions to income investors,…

Omor Ibne Ehsan | May 19, 2026 at 4:19 PM EDT

Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

The iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is the rare fund that has spent the past year being publicly threatened by…

Alex Sirois | May 15, 2026 at 11:40 AM EDT

Realty Income Has Raised Its Dividend 113 Consecutive Times. Here Is Why That Is Not Enough to Own It Right Now

Realty Income (NYSE:O | O Price Prediction) is dominating dividend feeds on Reddit and X again, with monthly-payer loyalists pointing…

Austin Smith | May 7, 2026 at 5:24 PM EDT

Vanguard High Dividend Yield ETF Delivers 67% Five-Year Returns Against Schwab U.S. Dividend Equity ETF’s Steadier 229% Decade Gain

Schwab U.S. Dividend Equity ETF (NYSEARCA: SCHD) and Vanguard High Dividend Yield ETF (NYSEARCA: VYM) sit on most income investors’…

Vandita Jadeja | May 6, 2026 at 10:32 AM EDT

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest…

Vandita Jadeja | May 4, 2026 at 8:55 AM EDT

10 Years, Zero Regrets: The Dividend Stocks I Keep Buying

Dividend stocks can be a pillar for long-term investing, generating passive income and offering stability even during tough environments. The…

Vandita Jadeja | Apr 30, 2026 at 10:40 AM EDT

Price Prediction: Why AbbVie’s Post-Humira Pivot Makes It a Strong Buy

Our AbbVie (NYSE:ABBV | ABBV Price Prediction) call lands on the constructive side of the ledger after a noisy but…

Lee Jackson | Apr 30, 2026 at 7:49 AM EDT

Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, Equinix, GE Healthcare, Kratos Defense, Meta Platforms, Oneok, Palantir Technologies, Wingstop, and More

Pre-Market Stock Futures: Futures are trading higher this morning after a messy Wednesday trading session that saw all major indices…

John Seetoo | Apr 25, 2026 at 6:35 AM EDT

Healthcare CEF Insiders Are Quietly Buying While 60% of Distributions Return Capital

Income investors shopping the healthcare aisle often land on Gabelli Healthcare & WellnessRx Trust (NYSE:GRX), a closed-end fund managed by…

Vandita Jadeja | Apr 23, 2026 at 4:04 PM EDT

These 5 Stocks Pay You Even When You’re Sleeping

Market volatility in 2026 has reminded investors that earned income alone is fragile. When tariff fears rattle equities and economic…

David Beren | Apr 21, 2026 at 3:34 PM EDT

GDV’s 6.1% Yield Faces a Hidden Test in 2026 Small-Cap Downturn

Gabelli Dividend & Income Trust (NYSE:GDV) trades near $29 and pays a $0.15 monthly distribution, up from $0.11 per month…

David Moadel | Apr 21, 2026 at 10:30 AM EDT

Canaccord Calls AbbVie a Core Holding With a $262 Target: Is This Biopharma’s Most Durable Compounder?

One of Wall Street’s top firms just made the bull case for AbbVie (NYSE:ABBV | ABBV Price Prediction) stock, initiating…

Vandita Jadeja | Apr 20, 2026 at 10:37 AM EDT

Why I Can’t Stop Buying AbbVie Stock

AbbVie (NYSE:ABBV | ABBV Price Prediction) has attracted persistent buying interest, and every pullback has drawn in value-focused investors. The…

Vandita Jadeja | Apr 17, 2026 at 10:22 AM EDT

AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit

AbbVie (NYSE:ABBV | ABBV Price Prediction) and Pfizer (NYSE:PFE) both reported fourth quarter earnings in early February. AbbVie posted record…

1 2 3 4 … 40

AbbVie : ABBV

All AbbVie Articles

The Dividend Stocks That Can Replace a $65,000 Income and What They’ll Cost You

Why retirees are banking on SCHD’s 15-year unbroken dividend streak

Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

Realty Income Has Raised Its Dividend 113 Consecutive Times. Here Is Why That Is Not Enough to Own It Right Now

Vanguard High Dividend Yield ETF Delivers 67% Five-Year Returns Against Schwab U.S. Dividend Equity ETF’s Steadier 229% Decade Gain

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash

10 Years, Zero Regrets: The Dividend Stocks I Keep Buying

Price Prediction: Why AbbVie’s Post-Humira Pivot Makes It a Strong Buy

Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, Equinix, GE Healthcare, Kratos Defense, Meta Platforms, Oneok, Palantir Technologies, Wingstop, and More

Healthcare CEF Insiders Are Quietly Buying While 60% of Distributions Return Capital

These 5 Stocks Pay You Even When You’re Sleeping

GDV’s 6.1% Yield Faces a Hidden Test in 2026 Small-Cap Downturn

Canaccord Calls AbbVie a Core Holding With a $262 Target: Is This Biopharma’s Most Durable Compounder?

Why I Can’t Stop Buying AbbVie Stock

AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit

3 Semiconductor Stocks to Buy While They Are Down in June

Claiming Social Security in 2027? One Key Move Could Boost Your Benefits Before You File

A $650,000 Portfolio That Could Send You to the Super Bowl Every Year

Claiming Social Security in 2027? One Key Move Could Boost Your Benefits Before You File

A $650,000 Portfolio That Could Send You to the Super Bowl Every Year

3 Semiconductor Stocks to Buy While They Are Down in June

Claiming Social Security in 2027? One Key Move Could Boost Your Benefits Before You File

AbbVie : ABBV

All AbbVie Articles

The Dividend Stocks That Can Replace a $65,000 Income and What They’ll Cost You

Why retirees are banking on SCHD’s 15-year unbroken dividend streak

Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

Realty Income Has Raised Its Dividend 113 Consecutive Times. Here Is Why That Is Not Enough to Own It Right Now

Vanguard High Dividend Yield ETF Delivers 67% Five-Year Returns Against Schwab U.S. Dividend Equity ETF’s Steadier 229% Decade Gain

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash

10 Years, Zero Regrets: The Dividend Stocks I Keep Buying

Price Prediction: Why AbbVie’s Post-Humira Pivot Makes It a Strong Buy

Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, Equinix, GE Healthcare, Kratos Defense, Meta Platforms, Oneok, Palantir Technologies, Wingstop, and More

Healthcare CEF Insiders Are Quietly Buying While 60% of Distributions Return Capital

These 5 Stocks Pay You Even When You’re Sleeping

GDV’s 6.1% Yield Faces a Hidden Test in 2026 Small-Cap Downturn

Canaccord Calls AbbVie a Core Holding With a $262 Target: Is This Biopharma’s Most Durable Compounder?

Why I Can’t Stop Buying AbbVie Stock

AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit

3 Semiconductor Stocks to Buy While They Are Down in June

Claiming Social Security in 2027? One Key Move Could Boost Your Benefits Before You File

A $650,000 Portfolio That Could Send You to the Super Bowl Every Year

Featured Reads

Claiming Social Security in 2027? One Key Move Could Boost Your Benefits Before You File

A $650,000 Portfolio That Could Send You to the Super Bowl Every Year